[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-331491-105":59,"doc-detail-331491-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","advancing-photodynamic-therapy-with-nano-conjugated-hypocrellin-mechanisms-and-clinical-applications","Advancing Photodynamic Therapy with Nano-Conjugated Hypocrellin: Mechanisms and Clinical Applications","","Hypocrellin-based photodynamic therapy (PDT) is emerging as a viable cancer treatment option, particularly when improved through nanoconjugation. This review explains how nano-conjugated hypocrellin boosts therapeutic efficacy and targeting accuracy by loading hypocrellin photosensitizers into carriers or by covalent binding. Upon light activation, these constructs generate singlet oxygen and other reactive oxygen species, driving oxidative stress that preferentially damages cancer cells while limiting harm to healthy tissue. Preclinical and clinical evidence highlights benefits such as increased solubility, better tumor penetration, longer circulation, and customized delivery. Future work aims to refine targeting, optimize release kinetics, and address biological barriers, including via stimuli-responsive nanocarriers and combination therapies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advancing-photodynamic-therapy-with-nano-conjugated-hypocrellin-mechanisms-and-clinical-applications/331491/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advancing-photodynamic-therapy-with-nano-conjugated-hypocrellin-mechanisms-and-clinical-applications/331491.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does nano-conjugated hypocrellin improve photodynamic therapy?","Question",{"text":112,"@type":113},"Nano-conjugation enables hypocrellin photosensitizers to accumulate preferentially in malignancies. Light activation then generates singlet oxygen and other ROS to drive selective oxidative damage to cancer cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which outcomes are reported from preclinical and clinical studies?",{"text":117,"@type":113},"Studies indicate improved water solubility, enhanced tumor penetration, longer circulation times, and tailored delivery. These factors are associated with fewer off-target effects and reduced overall toxicity.",{"name":119,"@type":110,"acceptedAnswer":120},"What directions does ongoing research focus on?",{"text":121,"@type":113},"Ongoing research targets better tumor targeting, improved drug-release kinetics, and overcoming biological obstacles. It also explores stimuli-responsive nanocarriers and combination therapies to strengthen treatment outcomes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},331491,1790487420,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","International Journal of Nanomedicine Dovepress  \n Open Access Full Text Article REVIEW  \nAdvancing Photodynamic Therapy with Nano-Conjugated Hypocrellin: Mechanisms and Clinical Applications  \nSheeja S Rajan , Rahul Chandran, Heidi Abrahamse   \nLaser Research Centre, Faculty of Health Sciences, University of Johannesburg, Johannesburg, South Africa  \nCorrespondence: Sheeja S Rajan; Heidi Abrahamse, Laser Research Centre, Faculty of Health Sciences, University of Johannesburg, Johannesburg, South Africa, Email [srajan@uj.ac.za](srajan@uj.ac.za); [habrahamse@uj.ac.za](habrahamse@uj.ac.za)  \n\n| Abstract: Hypocrellin-based photodynamic therapy (PDT) is developing as a viable cancer therapeutic option, especially when enhanced by nanoconjugation. This review investigates the methods by which nano-conjugated hypocrellin enhances therapeutic efficacy and precision when targeting cancer cells. These nanoconjugates encapsulate or covalently bind hypocrellin photosensitizers (PSs), allowing them to accumulate preferentially in malignancies. When activated by light, the nanoconjugates produce singlet oxygen and other reactive oxygen species (ROS), resulting in oxidative stress that selectively destroys cancer cells while protecting healthy tissues. We look at how they can be used to treat a variety of cancers. Clinical and preclinical studies show that they have advantages such as increased water solubility, improved tumor penetration, longer circulation times, and tailored delivery, all of which contribute to fewer off-target effects and overall toxicity. Ongoing research focuses on improving these nanoconjugates for better tumor targeting, drug release kinetics, and overcoming biological obstacles. Furthermore, the incorporation of developing technologies such as stimuli-responsive nanocarriers and combination therapies opens exciting opportunities for enhancing hypocrellin-based PDT. In conclusion, the combination of hypocrellin and nanotechnology constitutes a significant approach to cancer treatment, increasing the efficacy and safety of PDT. Future research will seek to create conjugates including hypocrellin, herceptin, and gold nanoparticles to induce apoptosis in human breast cancer cells in vitro, opening possibilities for therapeutic applications.\u003Cbr>Keywords: hypocrellin, cancer, photodynamic therapy, photosensitizer, nanoparticles |\n| --- |\n| Introduction\u003Cbr>Globally, cancer continues to be a leading cause of death primarily due to late detection and ineffective chemotherapy treatments.1 Approximately out of the 20 million newly reported cases, 10 million deaths were estimated in 2023 based on available data.2,3 Globally, roughly 1 in 5 men and 1 in 6 women will develop a tumor at some point in their lives, contributing to about 1 in 6 deaths.4 Numerous ecological and lifestyle aspects, including as infrared (IR) radiation, endogenous reactive oxygen species (ROS), carcinogenic compounds, and complex pathways involving topoisomerase and nuclease activities, influence the genesis of cancer.5 Conventional treatment options for cancer include chemotherapy, immunotherapy, radiation therapy, targeted therapy, endocrine therapy, and surgery.6 Regrettably, the existing therapeutic interventions exhibit notable limitations, include toxicities and side effects that make dose administration difficult.7,8 Hence, there is a pressing necessity for the development of innovative and more efficacious therapeutic approaches to enhance clinical outcomes. A minimally invasive therapeutic method for cancer and several non-cancerous illnesses is called photodynamic therapy (PDT) .9 PDT entails the elimination of undesirable cells or tissues through the induction of ROS production during photoactivation, wherein a photosensitizing agent is stimulated by light of specific wavelengths.10 When exposed to light, photosensitizers (PSs) and non-toxic dyes, interact with oxygen to produce ROS. These ROS can harm cellular components and cause cellular d","cbCaib4S7WOHg4Jx","https://ap.wps.com/l/cbCaib4S7WOHg4Jx","pdf",3346105,16,"English","# Introduction\n## Photodynamic therapy and its mechanism\n## Hypocrellins as photosensitizers\n## Limitations of conventional cancer treatments\n## Rationale for nano-conjugated delivery","[{\"question\":\"How does nano-conjugated hypocrellin improve photodynamic therapy?\",\"answer\":\"Nano-conjugation enables hypocrellin photosensitizers to accumulate preferentially in malignancies. Light activation then generates singlet oxygen and other ROS to drive selective oxidative damage to cancer cells.\"},{\"question\":\"Which outcomes are reported from preclinical and clinical studies?\",\"answer\":\"Studies indicate improved water solubility, enhanced tumor penetration, longer circulation times, and tailored delivery. These factors are associated with fewer off-target effects and reduced overall toxicity.\"},{\"question\":\"What directions does ongoing research focus on?\",\"answer\":\"Ongoing research targets better tumor targeting, improved drug-release kinetics, and overcoming biological obstacles. It also explores stimuli-responsive nanocarriers and combination therapies to strengthen treatment outcomes.\"}]","Advancing Photodynamic Therapy with Nano-Conjugated Hypocrellin: Mechanisms and Clinical Applications | PDF",1789993548]